for its Abbreviated New Drug Application (ANDA) for Prednisolone Acetate Ophthalmic Suspension USP, 1%. The approval has been granted to market a generic equivalent of Pred Forte Ophthalmic ...

Prednisolone acetate 1%; oph. susp; contains benzalkonium chloride, sulfites. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute ...

Prednisolone acetate 0.5%, neomycin (as sulfate) 0.35%, polymyxin B sulfate 10000 Units; per mL; oph. susp. To treat eyes: 1–2 drops every 3–4 hrs, or more often if necessary. To treat lids ...

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, ...

The FDA has expanded the approval of Dextenza (dexamethasone ophthalmic insert) to include pediatric treatment.

subjects treated with prednisolone acetate (p <0.001). Note: ACC (anterior chamber cells) were evaluated using SUN grading scale. Both VVN461 dose groups demonstrated statistically significant and ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...